Free Trial
→ My top 3 AI picks for the next decade (From The Oxford Club) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
$62.06
+2.1%		$73.88
$1.16
▼
$14.10
$2.69B-0.12189,291 shs691,135 shs
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
$9.46
+1.8%		$11.83
$2.31
▼
$15.10
$676.76M0.241.79 million shs1.11 million shs
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$21.58
+1.5%		$24.91
$20.91
▼
$42.21
$2.58B0.11.79 million shs1.27 million shs
Precigen, Inc. stock logo
PGEN
Precigen
$7.81
+2.8%		$7.25
$2.99
▼
$8.98
$2.78B0.925.69 million shs3.38 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
+2.12%-3.80%-18.89%-18.97%-8.59%
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
0.00%-2.27%-25.51%-14.85%+272.44%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
0.00%-6.98%-1.28%-38.80%-34.33%
Precigen, Inc. stock logo
PGEN
Precigen
0.00%-8.55%+16.92%+46.80%+142.55%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
$62.06
+2.1%		$73.88
$1.16
▼
$14.10
$2.69B-0.12189,291 shs691,135 shs
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
$9.46
+1.8%		$11.83
$2.31
▼
$15.10
$676.76M0.241.79 million shs1.11 million shs
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$21.58
+1.5%		$24.91
$20.91
▼
$42.21
$2.58B0.11.79 million shs1.27 million shs
Precigen, Inc. stock logo
PGEN
Precigen
$7.81
+2.8%		$7.25
$2.99
▼
$8.98
$2.78B0.925.69 million shs3.38 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
+2.12%-3.80%-18.89%-18.97%-8.59%
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
0.00%-2.27%-25.51%-14.85%+272.44%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
0.00%-6.98%-1.28%-38.80%-34.33%
Precigen, Inc. stock logo
PGEN
Precigen
0.00%-8.55%+16.92%+46.80%+142.55%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
0.00
N/AN/AN/A
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
2.78
Moderate Buy$24.14155.21% Upside
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
2.85
Moderate Buy$49.00127.06% Upside
Precigen, Inc. stock logo
PGEN
Precigen
2.50
Moderate Buy$13.6774.99% Upside

Current Analyst Ratings Breakdown

Latest IMMX, PGEN, GMTX, and NAMS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/5/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$50.00 ➝ $42.00
10/5/2026
Precigen, Inc. stock logo
PGEN
Precigen
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
9/30/2026
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
9/29/2026
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$21.00 ➝ $30.00
9/25/2026
Precigen, Inc. stock logo
PGEN
Precigen
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$12.00
9/24/2026
Precigen, Inc. stock logo
PGEN
Precigen
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$12.00
9/15/2026
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$15.00 ➝ $26.00
9/8/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$52.00
8/14/2026
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
8/11/2026
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$20.00 ➝ $19.00
8/10/2026
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$20.00 ➝ $25.00
(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/A$2.89 per shareN/A
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
N/AN/AN/AN/A$1.77 per shareN/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$22.50M114.65N/AN/A$5.97 per share3.61
Precigen, Inc. stock logo
PGEN
Precigen
$9.68M287.64N/AN/A$0.06 per share130.17
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/A
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
-$29.44M-$0.88N/AN/AN/AN/A-38.44%-34.72%11/6/2026 (Estimated)
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$203.82M-$2.16N/AN/AN/A-3,644.21%-34.81%-31.50%11/4/2026 (Estimated)
Precigen, Inc. stock logo
PGEN
Precigen
-$250.64M-$1.04N/A10.70N/A-183.98%423.75%84.39%11/12/2026 (Estimated)

Latest IMMX, PGEN, GMTX, and NAMS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2026Q3 2026
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
-$0.19N/AN/AN/AN/AN/A
11/4/2026Q3 2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$0.50N/AN/AN/A$7.54 millionN/A
8/7/2026Q2 2026
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
-$0.17-$0.18-$0.01-$0.18N/AN/A
8/5/2026Q2 2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$0.4819-$0.52-$0.0381-$0.52$2.83 million$3.70 million
8/4/2026Q2 2026
Precigen, Inc. stock logo
PGEN
Precigen
-$0.0121$0.05+$0.0621$0.05$27.98 million$54.98 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/AN/A
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
N/AN/AN/AN/AN/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/AN/AN/AN/AN/A
Precigen, Inc. stock logo
PGEN
Precigen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/A
71.49
71.49
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
N/A
25.13
25.13
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/A
9.03
9.03
Precigen, Inc. stock logo
PGEN
Precigen
2.15
4.58
3.89

Institutional Ownership

CompanyInstitutional Ownership
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
75.42%
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
11.26%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
89.89%
Precigen, Inc. stock logo
PGEN
Precigen
33.51%

Insider Ownership

CompanyInsider Ownership
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
12.90%
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
30.30%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
12.74%
Precigen, Inc. stock logo
PGEN
Precigen
41.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
3043.33 million37.74 millionNot Optionable
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
2171.54 million49.86 millionOptionable
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
100119.54 million104.31 millionOptionable
Precigen, Inc. stock logo
PGEN
Precigen
47356.51 million208.92 millionOptionable

Recent News About These Companies

Zacks Research Downgrades Precigen (NASDAQ:PGEN) to Hold
October 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31096036
Precigen (NASDAQ:PGEN) Downgraded by Zacks Research to Hold
October 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-precigen-nasdaq-pgen-downgraded-by-zacks-research-to-hold-2026-10-07/
PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know
October 5, 2026  |  zacks.comhttps://www.zacks.com/stock/news/3000302/pgen-stock-up-more-than-50-in-3-months-here-s-what-you-should-know?cid=cs-stocknewsapi-ft-analyst_blog|price_surge_/_plunge-3000302
Precigen (NASDAQ:PGEN) Stock Falls 6.5% - Here's Why
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31088118
Precigen (NASDAQ:PGEN) Stock Falls 6.5% - What's Next?
October 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-precigen-nasdaq-pgen-stock-falls-65-whats-next-2026-10-05/
PTC Therapeutics (NASDAQ:PTCT) versus Precigen (NASDAQ:PGEN) Head to Head Contrast
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31086638
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
October 2, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2999327/4-low-beta-healthcare-stocks-to-buy-amid-fears-of-another-rate-hike?cid=cs-stocknewsapi-ft-analyst_blog|investment_ideas-2999327
Precigen (NASDAQ:PGEN) Reaches New 52-Week High - Should You Buy?
October 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31078658
Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?
October 1, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2998591/precigen-pgen-soars-6-3-is-further-upside-left-in-the-stock?cid=cs-stocknewsapi-ft-fundamental_analysis|daily_price_change_5%-2998591
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
September 30, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2998371/pgen-vs-irwd-which-biotech-stock-offers-better-growth-potential?cid=cs-stocknewsapi-ft-analyst_blog|most_popular_stocks-2998371
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
September 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/pgen-vs-irwd-biotech-stock-150800736.html
Precigen: The FDA's Platform Technology Designation And The Institutional Crossover Effect
September 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4951004-precigen-the-fdas-platform-technology-designation-and-the-institutional-crossover-effect
Precigen (NASDAQ:PGEN) Hits New 12-Month High - Here's What Happened
September 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-precigen-nasdaq-pgen-hits-new-12-month-high-heres-what-happened-2026-09-30/
Head to Head Contrast: Emergent Biosolutions (NYSE:EBS) vs. Precigen (NASDAQ:PGEN)
September 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31068357
Precigen (PGEN) Gets FDA Recognition. Can it Cut the Cost of Developing New Drugs?
September 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/precigen-pgen-gets-fda-recognition-015839357.html
Bank of America Corp DE Buys 1,848,414 Shares of Precigen, Inc. $PGEN
September 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-buys-1848414-shares-of-precigen-inc-pgen-2026-09-27/
Precigen (PGEN) Gains FDA Platform Backing, Is The Stock Still Cheap?
September 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/precigen-pgen-gains-fda-platform-170940636.html
B Riley Securities initiates coverage of Precigen at buy
September 26, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/b-riley-securities-initiates-coverage-of-precigen-at-buy/ar-AA2cZ9VI
B. Riley Financial Upgrades Precigen (NASDAQ:PGEN) to "Strong-Buy"
September 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-b-riley-financial-upgrades-precigen-nasdaq-pgen-to-strong-buy-2026-09-26/
Precigen (PGEN) Secures FDA Platform Status For AdenoVerse And Future Therapies
September 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/precigen-pgen-secures-fda-platform-161139077.html
Precigen (NASDAQ:PGEN) Shares Gap Up - Here's What Happened
September 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-precigen-nasdaq-pgen-shares-gap-up-heres-what-happened-2026-09-25/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Gemini Therapeutics stock logo

Gemini Therapeutics NASDAQ:GMTX

$62.06 +1.29 (+2.12%)
As of 10/9/2026

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Immix Biopharma stock logo

Immix Biopharma NASDAQ:IMMX

$9.46 +0.17 (+1.83%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$9.45 -0.01 (-0.11%)
As of 10/9/2026 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

NewAmsterdam Pharma stock logo

NewAmsterdam Pharma NASDAQ:NAMS

$21.58 +0.32 (+1.51%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$21.58 0.00 (0.00%)
As of 10/9/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Precigen stock logo

Precigen NASDAQ:PGEN

$7.81 +0.21 (+2.76%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$7.80 -0.01 (-0.13%)
As of 10/9/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas